A Comprehensive Approach

Light-Based Scientific Innovations

Our innovations drive the advancement of vision preservation and improvement. We focus on early detection, intervention, and comprehensive degenerative disease monitoring. Our first area of focus is dry age-related macular degeneration (AMD)

Valeda® Light Delivery System

Valeda is the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD) to improve vision

Valeda photobiomodulation (PBM) treatment is non-invasive and targets disease at the cellular level. Valeda delivers select wavelengths of light that act on cellular mechanisms important to dry AMD and enhance mitochondrial function to improve cellular energy (ATP) production.

Unlike high-power lasers used for surgery, PBM involves low-intensity light that does not cause heat or damage, making it a safe and effective treatment option for ocular diseases such as dry AMD.

PBM has applications and is being studied across various fields, including dermatology, neurology, and ophthalmology, for conditions such as wound healing, neurodegenerative diseases, and macular degeneration.

Valeda is available in the US, EU, and UK, as well as select countries in Central and South America.

MyValeda.com »

AdaptDx Pro®

AdaptDx Pro is a portable dark adaptometer that measures the speed of dark adaptation. Impaired dark adaptation indicates rod-mediated retinal dysfunction before structural damage occurs. Testing with AdaptDx Pro offers functional insights beyond standard imaging tests and is an objective test for assessing the overall health of the retina.

Dark adaptation is the process by which the eyes adjust to low-light conditions after exposure to bright light. It involves the regeneration of photopigments, primarily rhodopsin, in the rod cells of the retina, which are more sensitive to dim light than cone cells. During this process, pupils dilate to allow more light into the eye, and the rods become increasingly responsive, enhancing vision in darkness over time.

Impaired dark adaptation can be a sign of retinal or systemic health issues. AdaptDx Pro equips eyecare professionals to enhance the long-term eye health of their patients.

AdaptDx Pro is available in the USA and Canada.

AdaptDxPro.com »

Nova™ Vision Testing System

The NOVA Vision Testing System analyzes the entire pathway for visual and neuro-visual disorders.

Visual Evoked Potential (VEP) is a non-invasive diagnostic test that measures the brain’s electrical response to visual stimuli. It evaluates the function of the visual pathways from the eyes to the visual cortex in the brain. During the test, visual stimuli – such as flashing lights or patterns – are presented to the patient while electrodes placed on the scalp detect neural activity.

Electroretinography (ERG) is a diagnostic test that measures the electrical activity of the retina in response to light stimuli. It assesses the function of the photoreceptors (rods and cones) and other retinal cells by detecting electrical signals generated when the retina processes light. ERG is used by physicians to diagnose and monitor various retinal conditions, such as retinitis pigmentosa, age-related macular degeneration (AMD), and diabetic retinopathy.

NOVA VEP is available in the US. NOVA (VEP and ERG)are available in the EU and other select countries.

Diopsys.com »

U.S. Indications for Use

The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, AND The absence of neovascular maculopathy or central-involving geographic atrophy After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

Indications for Use outside the U.S.*

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

*Indications for use determined by region. Contact LumiThera for more information.

As a precaution, patients have not been tested and should not be treated with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), or if they have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine). In addition, patients should not receive treatment within 30 days of using photosensitizing agents (e.g., topicals, injectables) that are affected by 590, 660, and/or 850 nm light before consulting with their physician.

Refer to the Valeda User Manual for full Important Safety Information.